[HTML][HTML] Advances in the design and development of SARS-CoV-2 vaccines
XL Peng, JSY Cheng, HL Gong, MD Yuan… - Military Medical …, 2021 - Springer
Since the end of 2019, coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The RNA …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The RNA …
[HTML][HTML] Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers
Data about the long-term duration of antibodies after SARS-CoV-2 vaccination are still
scarce and are important to design vaccination strategies. In this study, 231 healthcare …
scarce and are important to design vaccination strategies. In this study, 231 healthcare …
[HTML][HTML] An immunological review of SARS-CoV-2 infection and vaccine serology: innate and adaptive responses to mRNA, adenovirus, inactivated and protein …
The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which is defined by its positive …
respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which is defined by its positive …
Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary
M Tré-Hardy, R Cupaiolo, A Wilmet… - Journal of Infection, 2021 - Elsevier
Objectives Scarce data are currently available on the kinetics of antibodies after vaccination
with mRNA vaccines as a whole and, with mRNA-1273, in particular. We report here an ad …
with mRNA vaccines as a whole and, with mRNA-1273, in particular. We report here an ad …
[HTML][HTML] Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina
RE Chahla, RH Tomas-Grau, SI Cazorla… - The Lancet Regional …, 2022 - thelancet.com
Summary Background Gam-COVID-Vac (SPUTNIK V) has been granted emergency use
authorization in 70 nations and has been administered to millions worldwide. However …
authorization in 70 nations and has been administered to millions worldwide. However …
[HTML][HTML] Patients with liver cirrhosis show high immunogenicity upon COVID-19 vaccination but develop premature deterioration of antibody titers
K Willuweit, A Frey, M Passenberg, J Korth, N Saka… - Vaccines, 2022 - mdpi.com
SARS-CoV-2 infection is known to lead to severe morbidity and mortality in patients with
liver cirrhosis. For this reason, vaccination of these patients against COVID-19 is widely …
liver cirrhosis. For this reason, vaccination of these patients against COVID-19 is widely …
Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort …
A Parthymou, EE Habeos, GI Habeos, A Deligakis… - BMJ open, 2022 - bmjopen.bmj.com
Objectives Vaccination against SARS-CoV-2 has been extensively deployed during COVID-
19 pandemic. One efficient method to evaluate response to vaccination is the assessment of …
19 pandemic. One efficient method to evaluate response to vaccination is the assessment of …
IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workers
G Brisotto, E Muraro, M Montico, C Corso… - Clinica Chimica …, 2021 - Elsevier
Background and aims Monitoring the immune response against SARS-CoV-2 is pivotal in
the evaluation of long-term vaccine efficacy. Immunoglobulin G (IgG) antibodies represent …
the evaluation of long-term vaccine efficacy. Immunoglobulin G (IgG) antibodies represent …
[HTML][HTML] Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays
Objectives mRNA vaccines, including Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer), elicit
high IgG and neutralizing antibody (NAb) responses after the second dose, but the …
high IgG and neutralizing antibody (NAb) responses after the second dose, but the …
[HTML][HTML] Antibody persistence 6 months post-vaccination with BNT162b2 among health care workers
F Campo, A Venuti, F Pimpinelli, E Abril, G Blandino… - Vaccines, 2021 - mdpi.com
Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in
correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection …
correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection …